Back to News
Market Impact: 0.25
Tempest Therapeutics Receives Nasdaq Notice of Bid Price Below $1.00
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
On November 4, 2026, Tempest Therapeutics said Nasdaq Listing Qualifications Staff notified it that its common stock's closing bid price had remained below $1.00 for 30 consecutive business days. The article excerpt provides no further details on the company's compliance timeline or potential market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
TPST-0.55
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in